Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 34Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Uterine Cervical Neoplasms 9Esophageal Neoplasms 9Brain Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Solid Tumor 7Rectal Neoplasms 7Lymphoma 7Glioblastoma 7Carcinoma, Hepatocellular 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Hodgkin Disease 6Colorectal Neoplasms 6Colonic Neoplasms 6Carcinoma, Renal Cell 6Breast Neoplasms, Male 6Stomach Neoplasms 5Sarcoma 5Neuroendocrine Tumors 5Lymphoma, Large B-Cell, Diffuse 5Carcinoma, Transitional Cell 5Thyroid Neoplasms 4Ovarian Neoplasms 4

Interventions

lutetium Lu 177 dotatate 5copper dotatate CU-64 3Magnetic Resonance Spectroscopy 3lanreotide 2gallium Ga 68 dotatate 2Nivolumab 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Carboplatin 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1regorafenib 1pembrolizumab 1pasireotide 1irinotecan sucrosofate 1folfirinox 1cabozantinib 1abemaciclib 1X-Rays 1Temozolomide 1Somatostatin 1Resveratrol 1Radiosurgery 1Octreotide 1Ipilimumab 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡